HOWL Werewolf Therapeutics
- 1.350
- -0.040-2.88%
Werewolf Therapeutics News
Werewolf Therapeutics Is Maintained at Market Outperform by JMP Securities
Werewolf Therapeutics Analyst Ratings
BofA Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $10
JMP Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $4
JMP Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Cuts Target Price to $4
Buy Rating Affirmed for Werewolf Therapeutics Amid Strategic Advancements and Strong Financial Position
BofA Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $15
Werewolf Therapeutics Analyst Ratings
Leerink Partners Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $13
JMP Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $12
H.C. Wainwright Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $15
BofA Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $10
Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL) and Chimerix (CMRX)
Leerink Partners Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $13
Wedbush Adjusts Price Target on Werewolf Therapeutics to $8 From $9, Maintains Outperform Rating
Buy Rating Affirmed for Werewolf Therapeutics on Strong Candidate Progress and Promising Safety Profiles
Buy Rating Affirmed: Werewolf Therapeutics' Promising Pipeline and Financial Health
Werewolf Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
No Data